117043-46-6

Basic information

• Product Name: ETHYL (2,5-DIOXOIMIDAZOLIDIN-1-YL)ACETATE
• Synonyms: 1-IMidazolidineaceticacid, 2,5-dioxo-, ethyl ester;ethyl 2-(2,5-dioxoimidazolidin-1-yl)acetate
• CAS NO: 117043-46-6
• Molecular Formula: C₇H₁₀N₂O₄
• Molecular Weight: 186.17
• Mol File: 117043-46-6.mol

Chemical Properties

• Melting Point: 84-85 °C
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.303g/cm³
• Refractive Index: 1.49
• PKA: 8.09±0.70(Predicted)
• CAS DataBase Reference: ETHYL (2,5-DIOXOIMIDAZOLIDIN-1-YL)ACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL (2,5-DIOXOIMIDAZOLIDIN-1-YL)ACETATE(117043-46-6)
• EPA Substance Registry System: ETHYL (2,5-DIOXOIMIDAZOLIDIN-1-YL)ACETATE(117043-46-6)

Safety Data

• Hazardous Substances Data: 117043-46-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H10N2O4/c1-2-13-6(11)4-9-5(10)3-8-7(9)12/h2-4H2,1H3,(H,8,12)

Upstream product

• 461-72-3 2,4-imidazolidinedione 
• 105-39-5 chloroacetic acid ethyl ester 
• 105-36-2 ethyl bromoacetate 
• 96943-01-0 N,N'-bis(carboxymethyl)urea 
• 5589-84-4 N-(N-phenylsulfanylcarbonyl-glycyl)-glycine ethyl ester 
• 301-04-2 lead acetate 
• 2949-22-6 Glycine ethyl ester isocyanate 
• 5070-13-3 bis-(p-nitrophenyl) carbonate 
• 3369-33-3 H-Gly-Gly-OEt*HBr 
• 7150-63-2 diethyl N,N'-carbonylbisglycinate 
• 64-17-5 ethanol 
• 80258-94-2 hydantoin-3-acetic acid 
• 75-44-5 phosgene 
• 2087-41-4 glycyl glycine ethyl ester hydrochloride 

Downstream Products

• 80258-94-2 hydantoin-3-acetic acid 
• 1004111-37-8 C₁₈H₁₅ClN₂O₅ 

Relevant articles and documents

Combinatorial chemistry of hydantoins

Access to combinatorial chemistry of hydantoins is provided by convenient and versatile methods for the solid phase synthesis of libraries of 3,5-, 1,3- and 1,3,5-substituted hydantoins. The preparation of trisubstituted hydantoins features a Mitsunobu reaction for introduction of the substituent on N-1.

Synthesis of imidazolidine-2,4-dione and 2-thioxoimidazolidin-4-one derivatives as inhibitors of virulence factors production in Pseudomonas aeruginosa

In an attempt to counteract bacterial pathogenicity, a set of novel imidazolidine-2,4-dione and 2-thioxoimidazolidin-4-one derivatives was synthesized and evaluated as inhibitors of bacterial virulence. The new compounds were characterized and screened fo

Synthesis and structure-activity relationship studies of 2,4-thiazolidinediones and analogous heterocycles as inhibitors of dihydrodipicolinate synthase

Dihydrodipicolinate synthase (DHDPS), responsible for the first committed step of the diaminopimelate pathway for lysine biosynthesis, has become an attractive target for the development of new antibacterial and herbicidal agents. Herein, we report the di

HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY

The present invention relates to certain heterocyclic compounds of formula (1) that have the ability to inhibit lysine biosynthesis via the diaminopimelate biosynthesis pathway in certain organisms. As a result of this activity these compounds can be used

Identification of a New Class of Selective Excitatory Amino Acid Transporter Subtype 1 (EAAT1) Inhibitors Followed by a Structure-Activity Relationship Study

Screening of a small compound library at the three excitatory amino acid transporter subtypes 1-3 (EAAT1-3) resulted in the identification of compound (Z)-4-chloro-3-(5-((3-(2-ethoxy-2-oxoethyl)-2,4-dioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic aci

Hydantoine derivatives as CD38 inhibitors

The present invention relates to compounds of formula I which have CD38 inhibitory activity and are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of inflammatory diseases.

HYDANTOINE DERIVATIVES AS CD38 INHIBITORS

The present invention relates to compounds of formula (I) which have CD38 inhibitory activity and are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of inflammatory diseases.

Rhodanine-based tau aggregation inhibitors in cell models of tauopathy

Breaking up the crowd: The pathological aggregation of tau protein correlates closely with the progression of Alzheimer's disease. Rhodanine-based inhibitors of tau aggregation (e.g. 1) have been identified, and it has been shown that tau aggregation in a

Synthesis of N,N′-carbonyl-bis-amino acids and N,N′-carbonyl-bis-peptides

A new method for the preparation of N,N′-carbonyl-bis-amino acid esters by reaction of bis(4-nitrophenyl)carbonate with amino acid esters is described. When the carbonate reacts with two equivalents of a peptide ester, N,N′-carbonyl-bis(peptide ester) is obtained but, a hydantoin derivative is formed as a side product. The hydantoin derivative is a major product, when equimolar amounts are allowed to react. Usefulness of this method for preparation of larger N,N′carbonyl-bis-peptides is demonstrated by the synthesis of the respective product from C-terminal hexapeptide of Substance P linked to the Merrifield resin.

MECHANISM OF BASE-CATALYZED CYCLIZATION OF ETHYL N-(SUBSTITUTED AMINOCARBONYL)GLYCINATES

The cyclization rate constants have been measured of substituted ethyl N-(phenylaminocarbonyl)-, N-(alkylaminocarbonyl)-, and N-(phenylaminothiocarbonyl)glycinates RNHCXNHCH2CO2C2H5 (X=O,S).Logarithms of these constants increase with decreasing basicity of the amines down to the value of pKa(RNH2) = 5.5.The rate-limiting step of the reaction is formation of the tetrahedral intermediate.With ethyl N-(phenylaminocarbonyl)glycinates (whose pKa(RNH2) values are higher) this dependence, on the contrary, slightly decreases, and the acid-catalyzed splitting off of ethoxy group from the cyclic intermediate becomes rate-li miting.The cyclization rate of a series of ethyl N-(phenylaminothiocarbonyl)glycinates is practically independent of the pKa(RNH2) values, the change in the rate limiting step would take place at pH about 9.